Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.41 |
| ▸ | IDO1 | P14902 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687117 | 0.87 | CRBN (0.50) | MIFDDB1CRBN | |
| SCHEMBL21687132 | 0.84 | DDB1 (0.41) | DDB1CRBNIDO1RAB9ALMNA | |
| SCHEMBL21687130 | 0.79 | CASP3 (0.44) | DDB1CRBNIDO1MAPTRAB9A | |
| SCHEMBL23845941 | 0.74 | MPI (0.47) | MIFDDB1CRBNIDO1MAPT | |
| SCHEMBL21687109 | 0.72 | CRBN (0.52) | DDB1CRBN | |
| SCHEMBL21687113 | 0.72 | CRBN (0.50) | DDB1CRBN | |
| SCHEMBL21687111 | 0.69 | CRBN (0.45) | DDB1CRBN | |
| SCHEMBL21687112 | 0.69 | CRBN (0.46) | DDB1CRBN | |
| SCHEMBL21687108 | 0.68 | CRBN (0.56) | DDB1CRBN | |
| SCHEMBL21687125 | 0.66 | MPI (0.48) | MIFDDB1CRBNIDO1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292315-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI XINGYE PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2021-09-23 | — | — | US | disclosed |
| WO-2020020099-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海星叶医药科技有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292315-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | AIFM2, GPX1, AIFM1 | MIF 1349/4885DDB1 4153/4885CRBN 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.